Physician profile
Jerel David
NPI 1457844151
$7,923.00
in general payments reported to CMS, 2019-2025
56 companies · $5,491 in 2025
The $5,491 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $191 · 2023: $535 · 2024: $1,706 · 2025: $5,491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,974 · Long Term Medical Supply Or Device Loan: $1,180 · Education: $578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,974.49 |
| Long Term Medical Supply Or Device Loan | $1,180.03 |
| Education | $577.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,465.27 | 2024-2025 | |
| Pfizer INC. | $801.07 | 2024-2025 | |
| Lilly USA, LLC | $415.50 | 2022-2025 | Jaypirca, Verzenio |
| Seagen INC. | $377.65 | 2022-2025 | |
| Abbvie INC. | $365.21 | 2024-2025 | |
| Janssen Biotech, INC. | $328.44 | 2023-2025 | Darzalex, Erleada, Rybrevant |
| Daiichi Sankyo INC. | $291.19 | 2023-2025 | Enhertu, Injectafer, Datroway |
| Regeneron Healthcare Solutions, INC. | $279.48 | 2024-2025 | Libtayo |
| Merck Sharp & Dohme LLC | $220.55 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals Lp | $192.53 | 2024-2025 | Enhertu, Lynparza |
| Alexion Pharmaceuticals, INC. | $184.66 | 2024-2025 | Ultomiris |
| Sobi, INC | $168.57 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.55 | 2024-2025 | |
| Glaxosmithkline, LLC. | $143.65 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Recordati_rare_diseases_inc. | $143.60 | 2024-2025 | Sylvant, Enjaymo |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Morphosys, US INC. | $139.98 | 2023 | Monjuvi |
| Takeda Pharmaceuticals U.S.A., INC. | $137.00 | 2024-2025 | Iclusig, Ninlaro, Fruzaqla |
| Array Biopharma INC | $131.34 | 2024-2025 | Braftovi, Lorbrena, Mektovi |
| Jazz Pharmaceuticals INC. | $125.61 | 2024-2025 | |
| Boston Scientific Corporation | $114.41 | 2024 | Spaceoar Vue System - 10ml |
| E.R. Squibb & Sons, L.L.C. | $99.83 | 2024-2025 | Opdivo, Reblozyl, Opdualag |
| Incyte Corporation | $99.42 | 2024-2025 | Jakafi, Zynyz, Monjuvi |
| Astellas Pharma US INC | $99.17 | 2025 | Xtandi |
| Genentech USA, INC. | $88.04 | 2024-2025 | Tecentriq, Venclexta |
| Pharmacosmos Therapeutics INC. | $87.32 | 2024-2025 | Monoferric |
| Ipsen Biopharmaceuticals, INC | $85.17 | 2024-2025 | Onivyde, Somatuline Depot |
| Beone Medicines USA, INC. | $85.07 | 2025 | Brukinsa |
| Stemline Therapeutics INC. | $83.57 | 2025 | Orserdu |
| Beigene USA, INC. | $78.03 | 2024-2025 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $73.97 | 2024-2025 | |
| Genzyme Corporation | $70.64 | 2024-2025 | |
| Asd Specialty Healthcare, LLC | $69.84 | 2025 | |
| Celgene Corporation | $58.82 | 2025 | Reblozyl |
| Amneal Pharmaceuticals LLC | $53.24 | 2024-2025 | Alymsys, Avastin, Neupogen |
| Eisai INC. | $51.53 | 2024-2025 | |
| Tempus Ai, INC | $50.37 | 2025 | Xt Cdx |
| Caris Mpi, INC. | $44.66 | 2025 | Mi Cancer Seek |
| Puma Biotechnology, INC. | $37.63 | 2025 | |
| Coherus Oncology, INC. | $34.10 | 2025 | Loqtorzi |
| Amgen INC. | $32.72 | 2025 | |
| Sun Pharmaceutical Industries INC. | $32.26 | 2025 | |
| Pharmaessentia USA Corporation | $32.16 | 2025 | Besremi |
| Syndax Pharmaceuticals, INC. | $24.49 | 2025 | |
| Emd Serono, INC. | $24.10 | 2025 | |
| Gilead Sciences, INC. | $23.48 | 2025 | Trodelvy |
| Invivyd INC | $22.47 | 2025 | Pemgarda |
| Springworks Therapeutics, INC. | $22.27 | 2025 | Ogsiveo |
| Kyowa Kirin, INC. | $20.57 | 2025 | |
| Karyopharm Therapeutics INC. | $20.50 | 2025 | Xpovio |
| Sumitomo Pharma America, INC. | $19.75 | 2025 | Orgovyx |
| Geron Corporation | $19.30 | 2025 | Rytelo |
| Tolmar, INC. | $18.43 | 2025 | Rubraca, Eligard |
| Pharmaand Gmbh | $18.43 | 2025 | Rubraca |
| Exelixis INC. | $17.99 | 2025 | Cabometyx |
| Kite Pharma, INC. | $16.96 | 2025 | Yescarta |
| Servier Pharmaceuticals LLC | $14.44 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerel David listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.